Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Burkitt Lymphoma: early-phase trial registry
17 of 23 indexed Burkitt Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #724 of 28,707 conditions by registered trial count.
23 US clinical trials · 17 currently recruiting · #724 of 28,707 conditions by registered trial count
Burkitt Lymphoma: 23 US clinical trials tracked, 17 recruiting.
Burkitt Lymphoma is the subject of 23 registered US clinical trials on ClinicalTrials.gov, 17 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 20 in Phase 1-2 (earlier-stage). The most active sponsor is Medical College of Wisconsin, running 5 of these trials.
Enrollment posture brief
Registry condition burkitt-lymphoma
OPEN 17 | RECR 74% | LATE 0 | EARLY 20 | RANK #724 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Major Depressive Disorder (MDD) (74% recruiting · 23 trials)
Burkitt Lymphoma lists 17 open slots (74% of 23 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Burkitt Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Burkitt Lymphoma is recruiting above its size-band peers.
17 of 23 indexed trials (73.9%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Burkitt Lymphoma research.
Medical College of Wisconsin accounts for 5 of 23 trials (21.7%). 16 distinct sponsors appear on at least one study for this condition label.
-
Most Burkitt Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 23 trials that report a genuine target (sentinel values excluded). 20 of those (87%) plan for fewer than 100 participants.
-
Burkitt Lymphoma research is mostly interventional.
22 interventional and 1 observational studies make up this index (95.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
23 total, page 1 of 1
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Medical College of Wisconsin
NCT03375619
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
National Cancer Institute (NCI)
NCT03223610
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Stanford University
NCT06340737
Study of SGR-1505 in Mature B-Cell Neoplasms
Schrödinger
NCT05544019
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Merck Sharp & Dohme
NCT06395103
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
NCT04195633
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
National Cancer Institute (NCI)
NCT04739813
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
National Cancer Institute (NCI)
NCT07069699
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
Children's Hospital of Philadelphia
NCT03810196
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Acepodia Biotech
NCT05653271
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
Medical College of Wisconsin
NCT05794880
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
C. Babis Andreadis
NCT04545762
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics
NCT06533579
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
New York Medical College
NCT02393157
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Cancer Institute (NCI)
NCT05389423
Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
University of Washington
NCT07097363
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Medical College of Wisconsin
NCT05990465
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Masonic Cancer Center, University of Minnesota
NCT03674411
Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies
Medical College of Wisconsin
NCT05270057
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NCT03833180
A Safety Study of SGN-CD19A for B-Cell Lymphoma
Seagen
NCT01786135
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
Medical College of Wisconsin
NCT00849147
A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT01184885
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 15 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Burkitt Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Burkitt Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Burkitt Lymphoma page
23 registered trials, 17 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 17 Burkitt Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Medical College of Wisconsin sponsors the most Burkitt Lymphoma trials on record, review their full trial history before evaluating a specific study. See Medical College of Wisconsin's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Burkitt Lymphoma condition card totals 23 registered trials; most-linked intervention Cyclophosphamide; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.